Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

The enhanced immune response to the HIV gp160/LAMP chimeric gene product targeted to the lysosome membrane protein trafficking pathway.

Ruff AL, Guarnieri FG, Staveley-O'Carroll K, Siliciano RF, August JT.

J Biol Chem. 1997 Mar 28;272(13):8671-8.

2.

Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen.

Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, Wu TC.

Cancer Res. 1996 Jan 1;56(1):21-6.

3.

Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens.

Wu TC, Guarnieri FG, Staveley-O'Carroll KF, Viscidi RP, Levitsky HI, Hedrick L, Cho KR, August JT, Pardoll DM.

Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11671-5.

4.

Lysosome-associated membrane protein-1-mediated targeting of the HIV-1 envelope protein to an endosomal/lysosomal compartment enhances its presentation to MHC class II-restricted T cells.

Rowell JF, Ruff AL, Guarnieri FG, Staveley-O'Carroll K, Lin X, Tang J, August JT, Siliciano RF.

J Immunol. 1995 Aug 15;155(4):1818-28.

PMID:
7636236
5.

The motif Tyr-X-X-hydrophobic residue mediates lysosomal membrane targeting of lysosome-associated membrane protein 1.

Guarnieri FG, Arterburn LM, Penno MB, Cha Y, August JT.

J Biol Chem. 1993 Jan 25;268(3):1941-6.

Supplemental Content

Loading ...
Support Center